GlaxoSmithKline plc and Royal Dutch Shell plc: 2 income champions to protect you from Brexit risks

GlaxoSmithKline plc (LON: GSK) and Royal Dutch Shell Plc (LON: RDSB) are two companies that could be immune to Brexit risks.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s one concern dominating the minds of investors at the moment and that’s Brexit. Indeed, if Britain votes to leave the EU on 23 June, the country will be subject to a multi-year period of uncertainty, and it’s this uncertainty that will cause investors the most pain.

To protect against uncertainty and any adverse effects that may come as a result of Britain’s decision to leave the EU, investors could look to large international firms with well-covered dividend yields and well-positioned to succeed in any economic environment.

Defensive business 

GlaxoSmithKline (LSE: GSK) is one such company. The pharmaceuticals giant is a world leader in the production of consumer pharmaceutical products, such as over-the-counter medicines, toothpaste and painkillers. What’s more, the group has a large vaccines division as well as a stake in ViiV Healthcare, a joint venture dedicated to delivering advances in treatment and care for people living with HIV. It’s extremely unlikely that any one of these businesses will see a sudden drop-off in demand for their products in the event of a Brexit.

Moreover, this year Glaxo is on track to report its first year of earnings growth since 2011, so there’s already a significant amount of positive sentiment surrounding the group. City analysts expect the company to report earnings growth of 16% this year, followed by growth of 5% for 2017.

Management has already come out to confirm it’s on track to meet this target. In fact, the first quarter of 2016 was one of the most impressive in several years for the company. Sales increased by 11%, to £6.2bn and earnings per share, excluding exceptional items and adjusted for currency, rose 8% to 19.8p. Shares in Glaxo currently trade at a forward P/E of 15.9 and support a dividend yield of 5.7%.

Global oil company 

Royal Dutch Shell (LSE: RDSB) is another large international company that’s unlikely to be significantly affected by a leave vote. As one of the largest oil traders in Europe and one of the biggest integrated oil companies in the world, Shell is a vital part of the global economy. 

This means that the group is likely to continue to churn out returns for investors no matter what the future holds for the UK economy.

Over the next few years, Shell’s earnings should climb steadily higher as the company continues its integration of recently acquired BG Group and cuts costs further to deal with the slump in oil prices. Asset sales should bolster the enlarged group’s balance sheet while improving margins as low-return assets are sold off.

Shares in Shell currently trade at a forward P/E of 23.7 and support a dividend yield of 7.2%. Management has announced its commitment to the dividend for the foreseeable future so a payout should be secure no matter what the outcome on 23 June.

Rupert Hargreaves owns shares of GlaxoSmithKline and Royal Dutch Shell B. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Road 2025 to 2032 new year direction concept
Investing Articles

See the income from investing a £20k ISA in this UK stock before it goes ex-dividend on 9 April

Harvey Jones says this UK stock offers one of the highest yields on the FTSE 100. Investors need to act…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

What’s going on with the AstraZeneca share price now?

Dr James Fox explores the recent movements in the AstraZeneca share price and evaluates whether it's still a good long-term…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This S&P 500 stock is down 30% and the CEO just bought $10m worth of shares

Insiders only buy a stock for one reason – they expect its price to go up. So, this S&P 500…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

£5,000 invested in BAE Systems shares a month ago is now worth…

BAE Systems shares have been among the FTSE 100's best performers in recent years. The question is, can the defence…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

Here’s how a £20k ISA could generate £7,875 in monthly passive income

Have £20,000 ready to invest? Royston Wild explains how you could put this in a Stocks and Shares ISA to…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

By April 2027, £2,630 invested in Barclays shares could be worth…

Barclays shares have been flying. But what might happen to a chunk of money invested in the bank's stock over…

Read more »

Satellite on planet background
Investing Articles

MTI Wireless Edge: the 61p defence penny stock that’s delivered 10x the return of Rolls-Royce shares in 2026

Edward Sheldon has spotted a penny stock in the defence space that offers growth, value, dividend income, and share price…

Read more »

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing For Beginners

Is this the biggest bargain in the FTSE 100 right now?

Jon Smith reviews a FTSE 100 stock that's fallen by 18% so far this year that he believes could be…

Read more »